Menu Search
Equities

Abbisko Cayman Ltd

8ZD:DUS

Abbisko Cayman Ltd

Actions
  • Price (EUR)0.424
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

  • Revenue in HKD (TTM)20.62m
  • Net income in HKD-466.89m
  • Incorporated2018
  • Employees258.00
  • Location
    Abbisko Cayman LtdBuilding 3, No. 898Halei Road, Zhangjiang Hi-Tech ParkPudong New AreaSHANGHAI 200120ChinaCHN
  • Phone+86 2 168912098
  • Websitehttps://www.abbisko.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.